Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy
暂无分享,去创建一个
M. Negrini | A. Cuneo | S. Moretti | S. Martinelli | G. Rigolin | F. Quaglia | A. Bardi | F. Cavazzini | M. Ciccone | E. Saccenti | M. Dabusti | E. Tammiso | O. Sofritti | Giulia Daghia | E. Volta | Enrico Lista | Luca Formigaro | Maurizio Cavallari | P. Tomasi | E. Lista | F. M. Quaglia | Eleonora Volta | Olga Sofritti
[1] H. Döhner,et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. , 2016, Blood.
[2] M. Negrini,et al. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations , 2015, Genes, chromosomes & cancer.
[3] F. Stingo,et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens , 2015, Cancer.
[4] T. Stankovic,et al. Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial , 2015, Leukemia.
[5] E. Kimby,et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial , 2015, The Lancet.
[6] C. Fegan,et al. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease , 2014, British journal of haematology.
[7] E. Giné,et al. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption , 2014, Haematologica.
[8] H. Döhner,et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. , 2014, Blood.
[9] E. Campo,et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia , 2014, Leukemia.
[10] J. Byrd,et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.
[11] M. Hallek,et al. Management of chronic lymphocytic leukemia , 2014, Haematologica.
[12] R. Ulrich,et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. , 2014, Blood.
[13] T. Shanafelt,et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Michael Hallek,et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.
[15] M. Negrini,et al. Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups , 2014, Cancer medicine.
[16] P. Antal-Szalmás,et al. Serum Thymidine Kinase Activity: Analytical Performance, Age-Related Reference Ranges and Validation in Chronic Lymphocytic Leukemia , 2014, PloS one.
[17] K. Stamatopoulos,et al. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: A systematic reappraisal of classic cytogenetic data , 2014, American journal of hematology.
[18] K. Stamatopoulos,et al. Stereotyped B-cell receptors in chronic lymphocytic leukemia , 2014, Leukemia & lymphoma.
[19] N. Chiorazzi,et al. B cell receptor signaling in chronic lymphocytic leukemia. , 2013, Trends in immunology.
[20] Raul Rabadan,et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. , 2013, Blood.
[21] M. Ferracin,et al. Genetic subclonal complexity and miR125a-5p down-regulatio identify a subset of patients with inferior outcome in low-ris CLL patients , 2013, Oncotarget.
[22] G. Juliusson,et al. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients , 2013, American journal of hematology.
[23] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[24] R. Foà,et al. A mechanism-driven treatment for chronic lymphocytic leukemia? , 2013, The New England journal of medicine.
[25] R. Serra,et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. , 2013, Blood.
[26] R. Foà,et al. Clinical implications of the molecular genetics of chronic lymphocytic leukemia , 2013, Haematologica.
[27] Carlos López-Otín,et al. The evolutionary biography of chronic lymphocytic leukemia , 2013, Nature Genetics.
[28] D. Catovsky,et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. , 2013, Blood.
[29] M. Dyer,et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] N. Chiorazzi. Implications of new prognostic markers in chronic lymphocytic leukemia. , 2012, Hematology. American Society of Hematology. Education Program.
[31] M. Cazzola,et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. , 2012, Blood.
[32] H. Döhner,et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Kostas Stamatopoulos,et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. , 2012, Blood.
[34] T. Stankovic,et al. Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage , 2012, Leukemia.
[35] S. Pileri,et al. Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays , 2012, Leukemia.
[36] J. Gribben,et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia , 2012, Leukemia.
[37] Chris Pepper,et al. Defining the prognosis of early stage chronic lymphocytic leukaemia patients , 2012, British journal of haematology.
[38] D. Rossi,et al. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia , 2012, Journal of Translational Medicine.
[39] L. Pasqualucci,et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.
[40] E. Giné,et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.
[41] A. Sivachenko,et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.
[42] K. Do,et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] A. Knudson,et al. A continuum model for tumour suppression , 2011, Nature.
[44] G. Morgan,et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Andrew W. Greaves,et al. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. , 2010, Cancer genetics and cytogenetics.
[46] H. Döhner,et al. TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.
[48] D. Catovsky,et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation , 2010, Haematologica.
[49] T. Haferlach,et al. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters , 2010, Genes, chromosomes & cancer.
[50] T. Gornet,et al. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. , 2010, American journal of clinical pathology.
[51] D. Rossi,et al. Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome , 2010, American journal of hematology.
[52] Y. Pekarsky,et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression , 2010, Proceedings of the National Academy of Sciences.
[53] S. Fröhling,et al. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). , 2010, Best practice & research. Clinical haematology.
[54] Marie Sevov,et al. Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity. , 2010, Leukemia research.
[55] Andrea Califano,et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. , 2010, Cancer cell.
[56] M. Hallek,et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. , 2009, Blood.
[57] Francesco Bertoni,et al. Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome , 2009, Clinical Cancer Research.
[58] H. Nückel,et al. High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. , 2009, Clinical immunology.
[59] M. Boccadoro,et al. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia , 2009, Leukemia.
[60] D. Rossi,et al. The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness , 2009, Clinical Cancer Research.
[61] D. Rossi,et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study , 2009, British journal of haematology.
[62] I. Screpanti,et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. , 2009, Blood.
[63] Axel Benner,et al. Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway , 2008, Cell cycle.
[64] Susan O'Brien,et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. , 2008, Blood.
[65] P. Ghia,et al. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] E. Montserrat,et al. Chronic lymphocytic leukaemia: a short overview. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[67] S. Chiaretti,et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. , 2008, Blood.
[68] V. Boussiotis,et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. , 2008, Blood.
[69] T. Shanafelt,et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential , 2008, British journal of haematology.
[70] H. Döhner,et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. , 2008, Blood.
[71] G. Salles,et al. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. , 2008, Blood.
[72] F. Buccisano,et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. , 2008, Blood.
[73] T. Haferlach,et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping , 2007, Leukemia.
[74] T. Hamblin. Prognostic markers in chronic lymphocytic leukaemia. , 2007, Best practice & research. Clinical haematology.
[75] John C Reed,et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] Nikolaos Laoutaris,et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. , 2006, Blood.
[77] B. Huber,et al. Molecular pathogenesis of chronic lymphocytic leukemia. , 2006, Current molecular medicine.
[78] C. Mayr,et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. , 2006, Blood.
[79] M. Andreeff,et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] Anna Tramontano,et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. , 2004, The Journal of clinical investigation.
[81] Emili Montserrat,et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.
[82] R. Rosenquist,et al. Association between telomere length and VH gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications , 2003, British Journal of Cancer.
[83] C. Croce,et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[84] N. Chiorazzi,et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.
[85] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[86] W. Hilbe,et al. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. , 1998, Cancer research.
[87] L. Rassenti,et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.
[88] M. James,et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. , 1997, Blood.
[89] A Benner,et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.
[90] C B Harley,et al. Telomere end-replication problem and cell aging. , 1992, Journal of molecular biology.
[91] S. Knuutila,et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. , 1990, The New England journal of medicine.
[92] P. Sperryn,et al. Blood. , 1989, British journal of sports medicine.
[93] D. Rossi,et al. NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation , 2016, Leukemia.
[94] A. Kohlmann,et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients , 2014, Leukemia.
[95] Jeffrey A Jones,et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. , 2014, The Lancet. Oncology.
[96] T. Shanafelt,et al. CD 49 d Is the Strongest Flow Cytometry – Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia , 2014 .
[97] M. Negrini,et al. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters. , 2012, Blood.
[98] Luca Laurenti,et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. , 2012, Blood.
[99] M. Hallek,et al. Prognostic factors in chronic lymphocytic leukemia—what do we need to know? , 2011, Nature Reviews Clinical Oncology.
[100] T. Haferlach,et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype , 2009, Leukemia.
[101] T. Shanafelt. Predicting clinical outcome in CLL: how and why. , 2009, Hematology. American Society of Hematology. Education Program.
[102] K. Stamatopoulos,et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia , 2007, Leukemia.